Business
Senseonics Holdings, Inc. Reports First Quarter Financial Results
Q1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist™ automated insulin delivery (AID) system with Eversense®
About this update from Senseonics Holdings, Inc.
[{"type":"text","content":"Q1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist™ automated insulin delivery (AID) system with Eversense® 365 one-year continuous glucose monitor (CGM); twiist with Eversense 365 launch expected in Q3 GERMANTOWN, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights & Accomplishments: Generated revenue of $6.3 million in the first quarter of 2025CMS updates the 2025 physician fee schedule on April 9, 2025, providing reimbursement for a full year of usage with Eversense 365 retroactive to January 1, 2025 for all eligible Medicare beneficiariesExecuted a commercial development agreement to integrate Senseonics’ Eversense 365 CGM with Sequel’s twiist AID, targeting availability in Q3Completed submission of CE Mark application in Q1 2025 for Eversense 365 in European Union; launch expected in second half of 2025Announced software integration of Eversense 365 with SweetSpot™ centralized software platform for managing diabetes care, to provide Accountable Care Organizations (ACOs) with real-time actionable data “We continue to execute on our strategy to make Eversense easier for people with diabetes to access and more flexible to use, always driving to continually improve the world’s only long-duration CGM platform,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “Securing positive CMS reimbursement of our one-year CGM, effective from January 1, was a major milestone for access, and our collaboration with Sequel is the important next step towards providing a convenient solution that integrates state of the art continuous glucose monitoring and insulin delivery technologies. Together with progress towards launching Eversense 365 in Europe, collaborations such as Sweet Spot, and development on Gemini and Freedom, we are delivering advances to improve the lives of the people we serve.” First Quarter 2025 Results:Total revenue for the first quarter of 2025 was $6.3 million compared to $5.0 million for the first quarter of 2024. U.S. revenue was $4.5 million for the fir...